Evidence map›Paper›PMID 40711876›Full record

ArticleCell reports2025

Epicutaneous Staphylococcus aureus initiates cross-tissue IL-36R signaling for neutrophilic lung inflammation in a model of the atopic march.

Sabrina N Kline, Laine E Feller, Yoshine Saito, Dustin Dikeman, Christine Youn, Yu Wang, Zhiyang Li, Meng-Jen Wu, Jing Zhang, Cristina Pontaza and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Fibroblasts resistScience advances · 2026
    Article
  2. Update on environmental determinants of allergic diseases.The Journal of allergy and clinical immunology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sabrina N KlineDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Laine E FellerDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Yoshine SaitoSchool of Medicine, University of Maryland Baltimore, Baltimore, MD 21201, USA.
Dustin DikemanDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Christine YounDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Yu WangDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Zhiyang LiDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Meng-Jen WuDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Jing ZhangDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Cristina PontazaDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA.
Junela C HunatDepartment of Biological Sciences, Towson University, Towson, MD 21252, USA.
Christine T N PhamDepartment of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
Xinzhong DongDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Nathan K ArcherDepartment of Dermatology, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA. Electronic address: narcher2@jhmi.edu.

Funding

Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6M
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseR01AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI M Javad Aman · 2015 to 2026
$6.9M
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infectionR01AI146177 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, ARCHER, NATHAN K. · 2020 to 2024
$3.5M
Bridges to the Doctorate at Towson UniversityT32GM146694 · NIGMS · TOWSON UNIVERSITY · PI Elana S Ehrlich, BRET A HASSEL · 2022 to 2026
$2.0M
IL-36 responses in Staphylococcus aureus driven skin inflammationR01AR073665 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ARCHER, NATHAN K. · 2018 to 2022
$1.8M
Future Academic Scientists in DermatologyT32AR074920 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Luis Andres Garza · 2020 to 2026
$1.4M
NIAID NIH HHS R01 AI111205NIAID NIH HHS R01 AI146177NIAMS NIH HHS P30 AR073752NIAMS NIH HHS R01 AR073665NIAMS NIH HHS T32 AR074920NIGMS NIH HHS T32 GM146694
6 · The paper itself

Abstract

Patients with atopic dermatitis exhibit abundant Staphylococcus aureus skin colonization and an increased risk of atopic march diseases, including allergic rhinitis, food allergies, and asthma. We have previously shown that S. aureus skin exposure exacerbates allergic lung inflammation in an interleukin-36 receptor (IL-36R)-dependent manner. However, the cellular and molecular mechanisms by which S. aureus skin exposure and IL-36R signaling orchestrate the progression from skin to lung inflammation are unclear. Using a preclinical model of the atopic march, we found that S. aureus skin exposure promoted robust neutrophilic lung inflammation via keratinocyte- and lung epithelia-specific IL-36R signaling. Unexpectedly, neutrophil IL-36R signaling triggered neutrophil extracellular trap (NET) formation and augmented lung pathology. Importantly, anti-IL-36R monoclonal antibody (mAb) treatment prevented the development of neutrophilic lung inflammation. Collectively, our findings suggested that S. aureus skin exposure exacerbates lung inflammation via distinct IL-36R signaling mechanisms on epithelia and neutrophils, which has therapeutic potential in halting the progression of the atopic march.

Indexed as

Dermatitis, AtopicNeutrophilsPneumoniaReceptors, Interleukin-1Signal TransductionSkinStaphylococcus aureusAnimalsDisease Models, AnimalExtracellular TrapsHumansKeratinocytesLungMiceMice, Inbred C57BLReceptors, Interleukin-1atopic dermatitisatopic marchCP: ImmunologyCP: MicrobiologyIL-36immunotherapeuticinflammationlungNETsneutrophilic asthmaskinStaphylococcus aureus

Identifiers

PMID40711876
PMCPMC12461889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.